
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is poised for continued growth in the immuno-oncology, autoimmune disorders, and infectious diseases space with its proprietary technology platforms, robust pivotal trial data for its lead product Papzimeos, and market exclusivity through 2032. The recent increase in peak penetration assumption to 10% and label expansion opportunities, along with the strong launch trajectory and access to permanent J-code, are projected to drive increased revenue and potentially accelerate the company's timeline for cash flow breakeven. While there are inherent risks in the biopharmaceutical industry, Precigen has a strong commitment to maintaining a presence at key medical meetings and driving awareness and education for its product, positioning itself for long-term success.
Bears say
Precigen is facing challenges with converting patients into actual treatment, as only 25% of the enrolled 400 patients come from the community setting, and there is no disclosure on the conversion rate of hub-to-treatment. Additionally, larger institutions operate their own hub systems, creating competition for Precigen's patient hub. The company's commercial infrastructure may also take longer to ramp up, and with a J-code unlock in 2026, it may take multiple quarters for revenue to compound and achieve cash flow breakeven. As a result, there may be limited potential for stock growth in the near future.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares